Novavax Reports 2025 Financials
Maryland-based biotech firm Novavax reported its fourth quarter and full-year 2025 financial results. The company highlighted operational resilience and progress in its vaccine pipeline and global partnerships.
The company's financial turnaround saw a full-year 2025 net income of $440 million, a significant recovery from the $187 million net loss reported for the full year 2024. Total revenue for 2025 jumped to $1.1 billion, a 65% increase from $682 million in the previous year. A major driver of this performance is a strategic shift away from direct commercialization to a partnership-driven model. This new direction is highlighted by a significant collaboration with Sanofi, which has already resulted in Novavax earning $225 million in milestone payments during 2025. Looking ahead, the Sanofi deal could bring in up to $350 million in milestones for a combination COVID-19 and influenza vaccine. In a move to further leverage its technology, Novavax entered into a non-exclusive license agreement with Pfizer in January 2026. The deal allows Pfizer to use Novavax's Matrix-M adjuvant in its vaccine development and includes a $30 million upfront payment to Novavax, with the potential for an additional $500 million in milestone payments. The company's proprietary Matrix-M adjuvant is a cornerstone of its new strategy. Novavax is actively signing Material Transfer Agreements with major pharmaceutical and oncology companies to explore the utility of this technology in a wider range of vaccines. While partnerships on its COVID-19 vaccine and adjuvant technology are central, Novavax is also advancing its own early-stage pipeline. Preclinical research is underway for vaccine candidates targeting C. diff, shingles, and RSV, with plans to enter clinical trials with at least one program as early as 2027. This strategic pivot is part of a multi-phase transformation aiming for long-term growth through a diversified revenue base from multiple large pharmaceutical partners. The company is targeting non-GAAP profitability as early as 2028 by focusing on research and development innovation and expanding its partnership ecosystem. The Maryland-based biotech sector, where Novavax is a key player, contributes significantly to the state's economy. The industry adds $20 billion to the state's economy annually, with average salaries in the life sciences being notably higher than in other sectors.
